Rexgenero Appoints Huw Jones as a Non-Executive Director

Written by: Mike Wood
Published On: 12 Feb 2020

London, UK, 12 February 2020 - Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces that Dr Huw Jones has joined the Company’s Board as a non-executive director, and will chair the Company’s remuneration committee. This follows the appointment earlier this week of Dr David Horn Solomon as Chairman of Rexgenero’s Board.

Huw is currently CEO of Chronos Therapeutics Limited (Chronos), a spin out from the University of Oxford, UK focussed on the development of a therapies for behavioural brain diseases. He has completed a transformation of Chronos, including extracting the company from the university, restructuring the organisation and completing the acquisition of an early brain disease development portfolio from Shire PLC (now part of Takeda). Huw was recently voted European CEO of the Year, Drug Discovery by print and online publication European CEO Magazine, alongside industry leaders from companies such as Adidas, Unilever and Spotify in their respective sectors.

Huw is also CEO of Gen2 Neuroscience Limited (Gen2), a company based in Cambridge, UK focussed on tauopathies via interference with specific toxic types of extracellular tau. Gen2 is funded by the UK Dementia Discovery Fund.

David Horn Solomon, Rexgenero’s new Chairman commented, “Huw brings a huge amount of commercial, development and leadership experience from many senior industry roles. He joins Rexgenero as we ramp up recruitment for our Phase III SALAMANDER trials of REX-001 in patients with chronic limb-threatening ischaemia and start planning for the next stage of our growth and development.”

Huw Jones added, “The promise of cell and gene therapies has long been recognised. I believe that Rexgenero’s deep understanding of this fast-moving and exciting area, together with a late-stage clinical asset targeting a large global patient population positions it well for future success. I look forward to helping Rexgenero achieve this.”

Huw has held a number of senior leadership roles at pharmaceutical and biotech companies and founded strategy consultancy Daffodil Consulting LLP. Prior roles include non-executive director and then CEO of Ardana PLC; President, Europe for NASDAQ-quoted cardiovascular company CV Therapeutics Inc.; non-executive chairman of UK speciality pharma company Ashbourne Pharmaceuticals; and SVP Northern Europe at Elan Pharmaceuticals. He started his career at SmithKline Beecham (now part of Glaxo SmithKline PLC), where he was appointed in a wide number of commercial and business development roles of increasing responsibility over a decade.

Huw holds a PhD in Pharmacology from the University of Birmingham, UK.

Related links